Trials / Unknown
UnknownNCT06033820
Zanubrutinib+Lenalidomide+R-ICE in Relapsed/Refractory DLBCL
A Prospective, Single Arm, Open Label Study to Evaluate the Safety and Efficacy of Zanubrutinib, Lenalidomide With R-ICE Chemotherapy for Relapsed/Refractory Diffuse Large B-cell Lymphoma.
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- RenJi Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This is a prospective, single center, single arm, open label study of zanubrutinib, lenalidomide in combination with Rituximab-ICE for treatment of relapsed/refractory diffuse large B-cell lymphoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ZR2-ICE | * Drug: zanubrutinib Oral Capsule * Drug: lenalidomide Oral Capsule * Drug: R-ICE chemotherapy |
Timeline
- Start date
- 2023-10-12
- Primary completion
- 2025-06-30
- Completion
- 2025-06-30
- First posted
- 2023-09-13
- Last updated
- 2024-03-13
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06033820. Inclusion in this directory is not an endorsement.